Mazdutide and Orforglipron—New Evidence in Obesity and Diabetes | ClinicLens

Glucagon-like peptide 1 (GLP-1) receptor agonists and other incretin-based medications, especially the newer-generation long-acting medications, have transformed the treatment of type 2 diabetes, obesity, and related cardiometabolic disorders with broad-spectrum efficacy that is

Medical Literature · Updated 2026-08-10

← Back to articles

This standalone article is served from the ClinicLens content archive.

If the embedded page does not load in your browser, open it directly.